Qiagen N.V
QIAGEN N.V. develops and sells sample and assay technologies used to prepare, process, and analyze biological material in life sciences and molecular diagnostics. Its portfolio spans consumables, instruments, software, and related services that support workflows from sample preparation to test interpretation, with operations and sales across the Americas, Europe, Asia-Pacific, and other global markets.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueKits, reagents, and related consumables used to extract and prepare nucleic acids and biological samples.
Clinical assays and testing solutions used in healthcare and applied testing workflows.
Systems and platforms such as QIAcuity used to run molecular analysis workflows.
Digital tools, design hubs, and analysis software that support assay design and interpretation.
Technical service, customer support, training, and related workflow assistance.
Products
Reported · share of revenue- Diagnostic Solutions38.4 %
- Sample Technologies31.6 %
- PCR Nucleic Acid Amplification14.8 %
- Genomics NGS11.6 %
- Other3.6 %
Source: 20-F FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
QIAGEN sells to life science researchers, pharmaceutical and biotechnology developers, clinical laboratories, and other applied-testing customers that need reliable sample-to-insight workflows. The company also serves molecular diagnostics users in healthcare, including customers running infectious disease, oncology, and immune-response testing. Distribution is a mix of direct sales, digital channels, and third-party distributors depending on market and product type.
Buy sample preparation and analysis products for basic research and method development.
Use molecular tools, assays, and software in drug discovery, translational research, and biomarker workflows.
Purchase diagnostic assays and instruments for routine patient testing and specialized workflows.
Use QIAGEN workflows for non-clinical testing in areas such as food, environmental, and other applied markets.
Buy and resell products in markets served through indirect commercial structures.
Strategy
QIAGEN’s strategy is to connect sample preparation, assay content, instruments, and software into integrated workflows that simplify and standardize molecular testing. The company also emphasizes omnichannel customer engagement, digital ordering, and self-service tools to improve reach and retention across research and diagnostics markets. Global manufacturing, distribution hubs, and regional sales organizations support broad market coverage and localized execution.
Bundled instruments, consumables, and software increase customer stickiness and broaden usage across the testing workflow.
Self-service portals, eCommerce, and digital marketing reduce friction and support recurring orders across many customer types.
A mix of direct sales, subsidiaries, and distributors is needed to reach more than 160 countries efficiently.
Serving both research and diagnostics widens the addressable market and diversifies end-market exposure.
Geography
2025QIAGEN operates globally, with major commercial activity in the Americas, Europe, the Middle East and Africa, Asia Pacific, and Japan, including China. The company reports direct sales in more than 40 countries and delivers products to more than 160 countries, with a network of local subsidiaries, distributors, and two global distribution hubs. Key sites include Venlo, Hilden, Germantown, Shanghai, and Singapore, which support manufacturing, headquarters, and regional commercial functions.
Share of the revenue the company reports by geography.
Risks
QIAGEN is exposed to demand swings in research, diagnostics, and applied testing, where instrument purchases and assay volumes can vary with funding, clinical demand, and channel inventory. The company also faces execution risk from global distribution complexity, regulatory and quality requirements, and dependence on a small number of higher-profile product franchises and markets. Accounting risk is meaningful because acquisitions, contingent consideration, goodwill, and product provisions require judgment and can move reported results.
- Dependence on testing demand in key franchisesImpact: HighLikelihood: High
Sales volumes can be affected by changes in clinical demand, public health activity, and customer ordering patterns.
Exposure: QuantiFERON and related molecular diagnostics products
- Regulatory and quality complianceImpact: HighLikelihood: Medium
Diagnostics and life-science products must meet strict quality standards, and failures can trigger recalls, delays, or lost customer trust.
Exposure: Clinical and regulated products
- Goodwill and intangible asset impairmentImpact: HighLikelihood: Medium
Acquired businesses and brands are tested against discounted cash flow assumptions that may not hold if growth slows.
Exposure: Acquisition balances and CGUs
- Channel and inventory variabilityImpact: MediumLikelihood: Medium
A mix of direct and distributor-led sales can create timing differences, stocking changes, and forecasting noise.
Exposure: Global distributor markets
- Contingent consideration and valuation estimatesImpact: MediumLikelihood: Medium
Acquisition liabilities depend on probability-weighted milestone outcomes and other unobservable inputs.
Exposure: Business combinations
Accounting
Judgemental itemsGoodwill is tested at least annually using recoverable amount estimates and can create large non-cash charges if assumptions weaken.
Impact: Could affect reported earnings and equity materially.
Acquisition liabilities are remeasured using milestone probabilities, forecasts, and discount rates.
Impact: Changes can move income statement results period to period.
The company records estimated future claims and obligations for product defects and related matters.
Impact: Affects operating expense and liabilities.
Debt discount amortization, issuance costs, and conversion features affect interest expense and balance sheet presentation.
Impact: Influences financing costs and diluted share calculations.
Similar listed companies
Publicly listed companies with a comparable business focus.
QuidelOrtho Corp
QDEL · In Vitro & In Vivo Diagnostic Substances
QuidelOrtho Corp develops and markets diagnostic testing products used to detect, monitor, and help manage disease across clinical and decentralized care settings.
Niagen Bioscience, Inc.
NAGE · Medicinal Chemicals & Botanical Products
Quanterix Corp
QTRX · Laboratory Analytical Instruments
Quanterix Corp develops and commercializes ultra-sensitive life science instruments, assay kits, and related services used to measure proteins and biomarkers in biological samples.
Exagen Inc
XGN · Services-Medical Laboratories
Quest Diagnostics Incorporated
DGX · Services-Medical Laboratories
Quest Diagnostics is a U.S.-based clinical laboratory company that provides diagnostic testing, pathology, and related information services through a…
Neogen Corporation
NEOG · In Vitro & In Vivo Diagnostic Substances
Neogen Corp develops and sells products and services used to test food, feed, and agricultural inputs for safety and quality, while also providing genomics and animal safety solutions.
Last updated: 28/09/2026